Immunitybio Financial Statements From 2010 to 2024
| IBRX Stock | USD 6.81 0.23 3.27% |
Gross Profit 240 K | Market Capitalization 4.9 B | Enterprise Value Revenue 6.3 K | Revenue 302 K | Earnings Share (1.08) |
Immunitybio Total Revenue |
|
Check Immunitybio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunitybio main balance sheet or income statement drivers, such as Depreciation And Amortization of 11.2 M, Interest Expense of 135.7 M or Selling General Administrative of 91.7 M, as well as many exotic indicators such as Price To Sales Ratio of 3.9 K, Dividend Yield of 0.0 or Days Sales Outstanding of 1.8 K. Immunitybio financial statements analysis is a perfect complement when working with Immunitybio Valuation or Volatility modules.
Immunitybio | Select Account or Indicator |
Immunitybio Balance Sheet | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Immunitybio Income Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Immunitybio Cash Flow Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Ratios | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Immunitybio Valuation Data | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Immunitybio Fundamental Market Drivers
| Cash And Short Term Investments | 266.5 M |
Immunitybio Upcoming Events
| 14th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
About Immunitybio Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Immunitybio income statement, its balance sheet, and the statement of cash flows. Immunitybio investors use historical funamental indicators, such as Immunitybio's revenue or net income, to determine how well the company is positioned to perform in the future. Although Immunitybio investors may use each financial statement separately, they are all related. The changes in Immunitybio's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Immunitybio's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Immunitybio Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Immunitybio. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 90 K | 85.5 K | |
| Total Revenue | 622 K | 617.8 K | |
| Cost Of Revenue | 18.5 M | 13.5 M | |
| Stock Based Compensation To Revenue | 79.04 | 50.06 | |
| Sales General And Administrative To Revenue | 818.00 | 850.83 | |
| Research And Ddevelopement To Revenue | 343.82 | 376.18 | |
| Capex To Revenue | (49.17) | (51.63) | |
| Revenue Per Share | 0 | 0 | |
| Ebit Per Revenue | (580.97) | (610.02) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Immunitybio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Immunitybio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immunitybio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immunitybio Stock:Check out the analysis of Immunitybio Correlation against competitors. For more information on how to buy Immunitybio Stock please use our How to Invest in Immunitybio guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Complementary Tools for Immunitybio Stock analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |
Is Immunitybio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunitybio. If investors know Immunitybio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunitybio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.08) | Revenue Per Share 0.001 | Quarterly Revenue Growth (0.89) | Return On Assets (0.58) |
The market value of Immunitybio is measured differently than its book value, which is the value of Immunitybio that is recorded on the company's balance sheet. Investors also form their own opinion of Immunitybio's value that differs from its market value or its book value, called intrinsic value, which is Immunitybio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunitybio's market value can be influenced by many factors that don't directly affect Immunitybio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunitybio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunitybio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunitybio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.